History of the Schistosomiasis Vaccine Initiative
The Schistosomiasis Vaccine Initiative (SVI) was launched in 2008 through funding from Mr. Morton Hyman and the Blavatnik Charitable Foundation. In collaboration with researchers at James Cook University and The George Washington University, a promising antigen, Sm-TSP-2, was selected for development.
Timeline
November 2007
Sabin Vaccine Development receives its initial funding from private donors to establish SVI and develop the Sm-TSP-2 Schistosomiasis Vaccine.
March 2008
Sabin Vaccine Institute acquires the exclusive license to the intellectual property for Sm-TSP-2 antigen from the Queensland Institute of Medical Research. Patent applications are filed in the United States, Brazil, Australia and India.
January 2009
Development of the manufacturing process for Sm-TSP-2 Schistosomiasis Vaccine at The George Washington University begins.
Sabin Vaccine Development creates sustainable and cost effective methods for preventing disease due to human hookworm and schistosomiasis. Learn more about its efforts to develop safe, efficacious and low-cost vaccines.
In 2010, the Sabin Vaccine Institute’s Human Hookworm Vaccine Initiative (HHVI) celebrated its 10-year anniversary. Learn why HHVI is committed to developing a vaccine to prevent infection.
Interactive Map
Schistosomiasis affects nearly 200 million people globally – devastating communities in 74 countries – impairing children’s development while causing internal organ damage in adults.
Print this page
Email this page